1-20 of 74
Thomas R. Collins
Close
Sort by
News

CAR-T Produces Good Long-Term Outcomes in R/R CLL, Analysis Finds

Thomas R. Collins
Published: 2024
Abstract
January 2025
View News titled, CAR-T Produces Good Long-Term Outcomes in R/R CLL, Analysis Finds
News

Ibrutinib-Rituximab Outperforms Chemotherapy in Front-Line MCL, Trial Finds

Thomas R. Collins
Published: 2024
Abstract
January 2025
View News titled, Ibrutinib-Rituximab Outperforms Chemotherapy in Front-Line MCL, Trial Finds
News

Eliminating Modifiable Risk Factors Lowers Bleeding Risk in Patients With Cancer, VTE, Study Finds

Thomas R. Collins
Published: 2024
Abstract
January 2025
View News titled, Eliminating Modifiable Risk Factors Lowers Bleeding Risk in Patients With Cancer, VTE, Study Finds
News

Considerable Morbidity and Mortality Seen in AIHA, Long-Term Study Finds

Thomas R. Collins
Published: 2024
Abstract
January 2025
View News titled, Considerable Morbidity and Mortality Seen in AIHA, Long-Term Study Finds
News

Pirtobrutinib Combinations Effective in Small Study

Thomas R. Collins
Published: 2024
Abstract
December Supplement 2024
View News titled, Pirtobrutinib Combinations Effective in Small Study
News

MRD Helpful in Predicting Progression-Free Survival in CLL

Thomas R. Collins
Published: 2024
Abstract
December Supplement 2024
View News titled, MRD Helpful in Predicting Progression-Free Survival in CLL
News

A Trial of Nanoparticle Tracking of CAR-T Therapy Distribution in Patients with Extramedullary Myeloma Shows Promise

Thomas R. Collins
Published: 2024
Abstract
January 2025
View News titled, A Trial of Nanoparticle Tracking of CAR-T Therapy Distribution in Patients with Extramedullary Myeloma Shows Promise
News

MGUS Risk Assessment Over Time Yields Benefits, Study Shows

Thomas R. Collins
Published: 2024
Abstract
December 2024
View News titled, MGUS Risk Assessment Over Time Yields Benefits, Study Shows
News

Superhero and Villain

Thomas R. Collins
Published: 2024
Abstract
December 2024 Although shows like Supacell bring awareness to sickle cell disease, many media depictions contribute to stereotypes and misinformation.
View News titled, Superhero and Villain
News

Venetoclax Effective for Bridging to Transplant in R/R AML, Study Suggests

Thomas R. Collins
Published: 2024
Abstract
Mid-November 2024
View News titled, Venetoclax Effective for Bridging to Transplant in R/R AML, Study Suggests
News

New Risk Tool Shows Promise for Waldenström Macroglobulinemia

Thomas R. Collins
Published: 2024
Abstract
October 2024
View News titled, New Risk Tool Shows Promise for Waldenström Macroglobulinemia
News

Transfusions Linked With Mortality in General Population, Study Finds

Thomas R. Collins
Published: 2024
Abstract
August 2024
View News titled, Transfusions Linked With Mortality in General Population, Study Finds
News

Straight-to-Transplantation Approach Comparable to Remission Induction in Difficult Acute Myeloid Leukemia Cases

Thomas R. Collins
Published: 2024
Abstract
Mid-July 2024
View News titled, Straight-to-Transplantation Approach Comparable to Remission Induction in Difficult Acute Myeloid Leukemia Cases
News

Rituximab Maintenance in MCL Found Advantageous After Firstline Treatment With Bendamustine-Rituximab

Thomas R. Collins
Published: 2024
Abstract
Mid-July 2024
View News titled, Rituximab Maintenance in MCL Found Advantageous After Firstline Treatment With Bendamustine-Rituximab
News

Machine Learning Outperforms Full Blood Count in Iron Deficiency Screening

Thomas R. Collins
Published: 2024
Abstract
Mid-July 2024
View News titled, Machine Learning Outperforms Full Blood Count in Iron Deficiency Screening
News

Cross-Trial Comparison Analyses in R/R Multiple Myeloma

Thomas R. Collins
Published: 2024
Abstract
May 2024
View News titled, Cross-Trial Comparison Analyses in R/R Multiple Myeloma
News

Belantamab Mafodotin Induces Durable Response When Combined With Pom-Dex, Despite Ocular Effects

Thomas R. Collins
Published: 2024
Abstract
April 2024
View News titled, Belantamab Mafodotin Induces Durable Response When Combined With Pom-Dex, Despite Ocular Effects
News

Imetelstat Produces RBC Transfusion Independence in Lower-Risk Myelodysplastic Syndromes

Thomas R. Collins
Published: 2024
Abstract
March 2024
View News titled, Imetelstat Produces RBC Transfusion Independence in Lower-Risk Myelodysplastic Syndromes
News

Under the Microscope

Thomas R. Collins
Published: 2024
Abstract
March 2024 Hospital accreditation is necessary, but some think it goes too far.
View News titled, Under the Microscope
News

In the Long Run, Ibrutinib Brings Disease Control, but Cardiac Risks, in Older Patients with Untreated CLL

Thomas R. Collins
Published: 2024
Abstract
March 2024
View News titled, In the Long Run, Ibrutinib Brings Disease Control, but Cardiac Risks, in Older Patients with Untreated CLL